IRLAB Therapeutics AB
Current Promotions
No video available
Get in Touch
About
IRLAB discovers and develops novel treatments of Parkinson's disease and other CNS disorders. The company's most advanced drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), are in Phase IIb and are designed to treat some of the most difficult symptoms related to Parkinson's . In 2021, Ipsen, a specialty pharma company, acquired exclusive global rights to the development and commercialization of mesdopetam.
IRLAB has discovered and generated all its drug candidates and continues to discover innovative drug candidates for the treatment of CNS disorders through its proprietary systems biology-based Integrative Screening Process (ISP) research platform. In addition to IRLAB's strong clinical pipeline, the company is also progressing two preclinical programs, IRL942 and IRL757, towards Phase I studies. IRLAB is listed on Nasdaq Stockholm. More information on www.irlab.se.
Keywords
No keywords available
Amenities
No amenities listed yet
Upcoming Events
No upcoming events scheduled
Frequently Asked Questions
No FAQs available for this business.
Reviews
No reviews yet. Be the first to review!
Social Links
Photo Gallery
No photos available
Contact Information
Business Info
Location
Business Hours
Business hours not available
Own This Business?
Unclaimed
Take control of your business page to update information, respond to reviews, and more.
Claim This Business